Loading…
PAVmed Inc. is projected to decline to $5.40 by 2027, a -2% move from its current price of $5.50. PAVM is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $5.25 | $5.51 | $5.78 | +0.09% |
| Aug 6 | $5.15 | $5.51 | $5.90 | +0.19% |
| Aug 7 | $5.08 | $5.52 | $5.99 | +0.28% |
| Aug 8 | $5.02 | $5.52 | $6.08 | +0.37% |
| Aug 9 | $4.96 | $5.53 | $6.15 | +0.47% |
| Aug 10 | $4.92 | $5.53 | $6.22 | +0.56% |
| Aug 11 | $4.88 | $5.54 | $6.28 | +0.66% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.88 | $5.54 | $6.28 | +0.66% |
| Week 2 | $4.66 | $5.57 | $6.67 | +1.32% |
| Week 3 | $4.50 | $5.61 | $6.99 | +1.98% |
| Week 4 | $4.38 | $5.65 | $7.28 | +2.65% |
| Week 5 | $4.28 | $5.68 | $7.55 | +3.33% |
| Week 6 | $4.19 | $5.72 | $7.80 | +4.01% |
| Week 7 | $4.12 | $5.76 | $8.05 | +4.69% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. Its focus is on bringing medical devices and diagnostic tools to market to address significant health concerns.
Its lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck device. Its product pipeline also comprises EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc.
and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
PAVmed Inc. is a healthcare company with a focus on developing and commercializing medical devices and diagnostic solutions in the United States. The stock is currently priced at $5.20 and has a market cap of $37.23M, with a global rank of 4499.
A major floor 40.9% below — a decisive break under it would weaken the trend.
The nearest floor, 20.9% below — buyers have tended to step in here.
The nearest ceiling, 14.5% above — a clean break opens room to run.
A major ceiling 86.2% above — clearing it would confirm fresh momentum.
Key PAVM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PAVM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $5.14 | Buy | $5.06 | Buy |
| MA 10 | $5.10 | Buy | $5.15 | Buy |
| MA 20 | $5.37 | Buy | $5.27 | Buy |
| MA 50 | $5.43 | Buy | $5.76 | Sell |
| MA 100 | $7.16 | Sell | $6.83 | Sell |
| MA 200 | $8.69 | Sell | $9.39 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 43.51 | Neutral |
| Stoch RSI (14) | 35.56 | Neutral |
| CCI (20) | -81.11 | Neutral |
| Williams %R (14) | -73.72 | Info |
| MACD (12,26,9) | -0.03 | Sell |
| ROC (12) | -18.85 | Sell |
| Bollinger %B (20,2) | 0.25 | Neutral |
| Stochastic %K (14) | 26.28 | Neutral |
| TRIX (15) | -0.24 | Sell |
| Awesome (5,34) | -0.14 | Sell |
| Ultimate (7,14,28) | 52.28 | Neutral |
| Momentum (10) | -0.98 | Sell |
| Aroon Osc (25) | 16.00 | Buy |
| Hull MA (9) | 5.15 | Buy |
| ADX (14) | 15.09 | Neutral |
| ATR (14) | 0.24 | Info |
The near-term technical picture shows BEARISH sentiment despite an RSI of 50. The stock’s moving averages sit at $5.57 for the SMA50 and $8.94 for the SMA200, indicating a bearish longer-term backdrop relative to the longer-term trend. It trades with support at $4.35 and resistance at $6.30, placing it between key levels.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.35 | $5.50 | $7.67 | 0% | Neutral | |
| $4.01 | $5.40 | $7.83 | -2% | Neutral | |
| $4.57 | $6.49 | $9.99 | +18% | Neutral | |
| $5.22 | $7.76 | $12.51 | +41% | Bullish | |
| $5.41 | $8.37 | $14.01 | +52% | Bullish | |
| $4.72 | $7.60 | $13.13 | +38% | Bullish | |
| $4.14 | $6.91 | $12.30 | +26% | Bullish | |
| $4.42 | $7.63 | $13.93 | +39% | Bullish | |
| $3.89 | $6.94 | $12.97 | +26% | Bullish | |
| $4.48 | $8.26 | $15.77 | +50% | Bullish | |
| $3.90 | $8.40 | $17.53 | +53% | Bullish | |
| $9.55 | $21.23 | $48.83 | +286% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $4.35 | $5.50 | $6.83 | +0.00% |
| September 2026 | $4.96 | $5.99 | $7.53 | +8.90% |
| October 2026 | $4.90 | $5.99 | $7.67 | +0.00% |
| November 2026 | $4.61 | $5.70 | $7.40 | -4.91% |
| December 2026 | $4.67 | $5.83 | $7.67 | +2.31% |
Click any year to see its month-by-month PAVM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
PAVmed Inc.'s 2026 outlook centres on $5.50, within a $4.35 to $7.67 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, PAVM could reach as high as $7.83, with a base case around $5.40 and support toward $4.01 — roughly -2% from $5.50. Price action looks broadly range-bound.
Expect PAVM to range from $4.57 to $9.99 through 2028. The $6.49 average target implies a +18% move from current prices. That is up +20% on the projected 2027 average. A consolidation phase looks the most probable path here.
The PAVM price prediction for 2029 points to an average of $7.76 (low $5.22, high $12.51) — a potential gain of +41% on today's $5.50. Momentum favours further upside here.
In 2030, PAVM is projected to trade between $5.41 and $14.01, averaging $8.37 — a potential gain of +52% from today's $5.50. That is up +8% on the projected 2029 average. Buyers look set to stay in control over this stretch.
PAVmed Inc.'s 2031 outlook centres on $7.60, within a $4.72 to $13.13 range. That is -9% versus the projected 2030 average. That marks a +38% change versus current levels. Momentum favours further upside here.
By 2032, PAVM could reach as high as $12.30, with a base case around $6.91 and support toward $4.14 — roughly +26% from $5.50. Buyers look set to stay in control over this stretch.
Expect PAVM to range from $4.42 to $13.93 through 2033. The $7.63 average target implies a +39% move from current prices. That is up +10% on the projected 2032 average. Momentum favours further upside here.
The PAVM price prediction for 2034 points to an average of $6.94 (low $3.89, high $12.97) — a potential gain of +26% on today's $5.50. Buyers look set to stay in control over this stretch.
In 2035, PAVM is projected to trade between $4.48 and $15.77, averaging $8.26 — a potential gain of +50% from today's $5.50. That is up +19% on the projected 2034 average. Momentum favours further upside here.
PAVmed Inc.'s 2040 outlook centres on $8.40, within a $3.90 to $17.53 range. That is up +2% on the projected 2035 average. That marks a +53% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, PAVM could reach as high as $48.83, with a base case around $21.23 and support toward $9.55 — roughly +286% from $5.50. Momentum favours further upside here.
Investing $1,000 in PAVM today (≈ 181.818182 PAVM) could be worth
$3,859.71
+$2,859.71 (+286%) by 2050 · US Dollar
Based on the average projected PAVM price of $21.23 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PAVMwould be worth at today's price.
$1,000 invested in PAVM on Jul 31, 2025 (≈ 57.870368 PAVM) would be worth
$318.29
-$681.71 (-68.2%) today · 0.32× · US Dollar
Based on a PAVM entry price of $17.28 vs. today's $5.5.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.74 | $1,160.34 | +16.0% |
| 1 month ago | $6.3 | $873.02 | -12.7% |
| 3 months ago | $8.53 | $644.78 | -35.5% |
| 6 months ago | $9.35 | $588.24 | -41.2% |
| 1 year ago | $17.28 | $318.29 | -68.2% |
| All time (5.0y) ago | $3,424.5 | $1.61 | -99.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PAVM forecast.
Our base-case forecast reaches $11.00 around 2050.
Implied market cap at $11.00: $78.75M
Long-range forecasts show a bullish trajectory with rising average prices and substantial upside potential by the mid- to late-2020s and into the 2030s and beyond. For 2030, the model projects an avg price of $8.27 with a max of $14.33 and a min of $5.12, for a 59% ROI and a BULLISH sentiment. The 2040 forecast calls for an avg of $7.80 with a max of $17.11 and a min of $3.51, for a 50% ROI and a BULLISH sentiment.
By 2050, the avg price is projected at $21.48 with a max of $49.41 and a min of $9.67, delivering a 313.1% ROI and a BULLISH sentiment. These figures indicate meaningful upside over the long term, though they are not guarantees and bear inherent uncertainty.
Tap a question to reveal the answer.
The forecast for 2030 shows an avg price of $8.27, a max of $14.33, and a min of $5.12, with a 59% ROI and a BULLISH sentiment.
Forecasts indicate a bullish sentiment from 2028 onward, with rising averages and substantial upside by 2030 and beyond (e.g., 2030 avg $8.27, ROI 59%; 2050 avg $21.48, ROI 313.1%). However, early years show neutral or modest returns, and these are estimates, not guarantees.
According to the forecast, the max price by 2050 is $49.41, which does not reach $50.
The current price is $5.20 and the market cap is $37.23M.
The 30-day range is from $3.58 to $7.56.
PAVmed Inc. Community Discussion
0Share your PAVmed Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.